Newbridge Financial Services Group Inc. Sells 1,395 Shares of DexCom, Inc. (NASDAQ:DXCM)

Newbridge Financial Services Group Inc. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 72.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 535 shares of the medical device company’s stock after selling 1,395 shares during the quarter. Newbridge Financial Services Group Inc.’s holdings in DexCom were worth $61,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Team Hewins LLC raised its stake in shares of DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after buying an additional 83 shares during the last quarter. Bleakley Financial Group LLC lifted its stake in shares of DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC boosted its position in shares of DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the last quarter. Gulf International Bank UK Ltd grew its stake in shares of DexCom by 0.3% during the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares during the period. Finally, Harbor Investment Advisory LLC increased its holdings in DexCom by 13.1% in the first quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock valued at $120,000 after purchasing an additional 100 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Piper Sandler restated an “overweight” rating and set a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Wells Fargo & Company decreased their price objective on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday. Morgan Stanley reduced their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Finally, JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $112.25.

Insider Activity

In related news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock worth $126,390 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 2.1 %

Shares of DexCom stock opened at $65.68 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The business’s 50 day simple moving average is $70.11 and its 200 day simple moving average is $105.61. The firm has a market cap of $26.12 billion, a PE ratio of 42.37, a P/E/G ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. The firm’s revenue was up 15.3% on a year-over-year basis. On average, analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.